Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Infliximab

5

XVII.e Pneumocystis jiroveci pneumonia

1
Last update : 06/04/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist
See also under
Biosimilars
1
Infliximab biosimilar
1
TNF-alpha antagonists / inhibitors
5

Publications

Pneumocystis pneumonia associated with infliximab in Japan.
The New England journal of medicine 2007 Nov 01;357;1874-6 2007 Nov 01
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
Digestive diseases and sciences 2007 Jun;52;1481-4 2007 Jun
Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis.
Internal medicine (Tokyo, Japan) 2006;45;685-8 2006
Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease.
Inflammatory bowel diseases 2004 Sep;10;657-60 2004 Sep
Pneumocystis carinii pneumonia following a second infusion of infliximab.
Rheumatology (Oxford, England) 2002 Aug;41;951-2 2002 Aug

Powered by

  • ^
  • Contact
  • Cookies
  • About

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies